Cool technology reduces dose interval of #IL17AFi To…every 6 to 12 months! #Antibody ORKA-002 has end of arms w YTE substitution prolonging circulation of drug Lasts longer than #bimekizumab Easier for adherence! #EULAR2025 @RheumNow @eular_org #abstPOS0016 https://t.co/KcKaIe0WMs